Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema.

Autor: Alsaedi NG; King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.; King Abdullah Medical City, Makkah, Saudi Arabia., Alselaimy RM; College of Medicine, King Saud University, Riyadh, Saudi Arabia., Alshamrani AA; King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia., AlAjmi M; Albahar Eye Centre, Kuwait City, Kuwait., Khandekar R; King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia., Al-Dhibi H; King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia., Al-Abdullah AA; King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia.
Jazyk: angličtina
Zdroj: Clinical ophthalmology (Auckland, N.Z.) [Clin Ophthalmol] 2021 Jul 13; Vol. 15, pp. 2975-2980. Date of Electronic Publication: 2021 Jul 13 (Print Publication: 2021).
DOI: 10.2147/OPTH.S316271
Abstrakt: Purpose: To compare the visual and anatomic outcomes of aflibercept versus ranibizumab as a second line treatment for persistent diabetic macular edema (DME) after initial bevacizumab injections.
Methods: In this retrospective cohort study, patients with center-involved DME of ≥ 300 μm thickness after bevacizumab intravitreal injections in 2015-2019 were included. Those treated with ranibizumab (R) and aflibercept (A) were grouped as group R and group A, respectively. The change in central macular thickness (CMT) measured by optical coherence tomography (OCT) and the best corrected distance visual acuity (BCVA) before and after three-monthly anti-VEGF injections (anti-VEGF) in group R and group A were compared and reviewed.
Results: There were 80 eyes of 75 patients in group R and 80 eyes of 72 patients in group A. The initial bevacizumab injections in group R and group A varied significantly (p = 0.01). The median change of the CMT after the three injections was not significantly different in group R (80 μm) and group A (81.5μm) (p = 0.7). The improvement of BCVA in group R and group A was not significant (p = 0.5). Dry macula was noted in 1 vs 14 eyes in group R vs group A.
Conclusion: After treating refractory DME with initial bevacizumab injections, 3 injections of either aflibercept or ranibizumab had similar anatomic and functional outcomes. Aflibercept achieved dry macula in more eyes with refractory DME compared to ranibizumab.
Competing Interests: The authors declare that they have no conflicts of interest.
(© 2021 Alsaedi et al.)
Databáze: MEDLINE
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje